In this study, we aimed to describe the clinicopathological, molecular, and transcriptomic profiles of invasive H2L breast carcinomas compared to HER2-negative and HER2-positive carcinomas to determine whether some differences between these tumor categories could explain the known differences in response to treatments. This evidence concerns the gene ERBB2 and carcinoma.